Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
ARVINAS, INC. (ARVN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
4
| Peck Ronald (Chief Medical Officer) has filed a Form 4 on ARVINAS, INC.|
Txns:
| Sold 1,324 shares
@ $24.3871, valued at
$32.3k
Exercised 4,010 restricted stock units
@ $0 |
|
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 06/08/2023 |
8-K
| Investor presentation |
| 05/05/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/03/2023 |
4
| Taylor Ian (Chief Scientific Officer) has filed a Form 4 on ARVINAS, INC.|
Txns:
| Sold 1,051 shares
@ $29.53, valued at
$31k
Exercised 2,685 restricted stock units
@ $0 |
|
| 03/03/2023 |
4
| Houston John G (President and CEO) has filed a Form 4 on ARVINAS, INC.|
Txns:
| Sold 5,878 shares
@ $29.53, valued at
$173.6k
Exercised 17,510 restricted stock units
@ $0 |
|
| 03/03/2023 |
4
| Cassidy Sean A (CFO) has filed a Form 4 on ARVINAS, INC.|
Txns:
| Sold 1,745 shares
@ $29.53, valued at
$51.5k
Exercised 4,791 restricted stock units
@ $0 |
|
| 02/24/2023 |
4
| Cassidy Sean A (CFO) has filed a Form 4 on ARVINAS, INC.|
Txns:
| Granted 19,125 shares
@ $0
Granted 57,450 options to buy
@ $34.37, valued at
$2M
|
|
| 02/24/2023 |
4
| Peck Ronald (Chief Medical Officer) has filed a Form 4 on ARVINAS, INC.|
Txns:
| Granted 19,125 shares
@ $0
Granted 57,450 options to buy
@ $34.37, valued at
$2M
|
|
| 02/24/2023 |
4
| Houston John G (President and CEO) has filed a Form 4 on ARVINAS, INC.|
Txns:
| Granted 61,975 shares
@ $0
Granted 186,250 options to buy
@ $34.37, valued at
$6.4M
|
|
| 02/24/2023 |
4
| Taylor Ian (Chief Scientific Officer) has filed a Form 4 on ARVINAS, INC.|
Txns:
| Granted 19,125 shares
@ $0
Granted 57,450 options to buy
@ $34.37, valued at
$2M
|
|
| 02/24/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/23/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 9.3% stake in Arvinas, Inc. |
| 02/14/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 4.4% stake in ARVINAS INC |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 8.4% stake in Arvinas Inc. |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 10.6% stake in ARVINAS INC |
| 02/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 8.2% stake in Arvinas, Inc. |
| 01/09/2023 |
8-K
| Investor presentation |
| 12/23/2022 |
3
| Loomis David K (Chief Accounting Officer) has filed a Form 3 on ARVINAS, INC. |
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/19/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 12/16/2022 |
8-K
| Quarterly results |
| 12/08/2022 |
8-K
| Quarterly results |
| 11/22/2022 |
8-K
| Quarterly results |
| 11/22/2022 |
8-K
| Quarterly results |
|
|
|